Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2013, Article ID 581751, 7 pages
Review Article

Targeting Inflammation in Emerging Therapies for Genetic Retinal Disease

Eye Care Centre, Department of Ophthalmology and Visual Science, University of British Columbia, 2550 Willow Street, Vancouver, BC, Canada V5Z 3N9

Received 5 November 2012; Accepted 20 January 2013

Academic Editor: David A. Hollander

Copyright © 2013 Ishaq A. Viringipurampeer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Genetic retinal diseases such as age-related macular degeneration and monogenic diseases such as retinitis pigmentosa account for some of the commonest causes of blindness in the developed world. Diverse genetic abnormalities and environmental causes have been implicated in triggering multiple pathological mechanisms such as oxidative stress, lipofuscin deposits, neovascularisation, and programmed cell death. In recent years, inflammation has also been highlighted although whether inflammatory mediators play a central role in pathogenesis or a more minor secondary role has yet to be established. Despite this, numerous interventional studies, particularly targeting the complement system, are underway with the promise of novel therapeutic strategies for these important blinding conditions.